New York, Global Insight Services have recently published a report on Atopic Dermatitis – Drug Pipeline Landscape, 2022. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It’s characterized by inflamed skin that may crack and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an immune system response that causes the inflamed skin and other symptoms.
Request for a PDF sample copy of report: https://www.globalinsightservices.com/request-sample/GIS31002
Report Highlights
Global Insight Service’s, Atopic Dermatitis – Drug Pipeline Landscape, 2022 report provides an overview of the Atopic Dermatitis pipeline drugs. This report covers detailed insights on Atopic Dermatitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Atopic Dermatitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Some of the key players involved in development of Atopic Dermatitis therapeutics are :
Key Players
• 3SBio Inc
• AbbVie
• Aclaris Therapeutics, Inc.
• Akaal Pharma Pty Ltd
• Akesobio Australia Pty Ltd
• Allakos, Inc.
• Amgen
• Amtixbio Co Ltd
• Amytrx Therapeutics, Inc
• AOBiome LLC
• Arcutis Biotherapeutics, Inc.
• Arena Pharmaceuticals
• Arjil Pharmaceuticals LLC
• Asana BioSciences
• ASLAN Pharmaceuticals
• AstraZeneca
• Atrapos Therapeutics LLC
• Avixgen Inc
Buy this report: https://www.globalinsightservices.com/checkout/single_user/GIS31002/
With Global Insight Services, you receive:
- 10-year forecast to help you make strategic decisions
- In-depth segmentation which can be customized as per your requirements
- Free consultation with lead analyst of the report
- Excel data pack included with all report purchases
- Robust and transparent research methodology
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700